This AOCNP 2026/2027 study document provides 135+ concise questions and answers for students and advanced practice nurses reviewing high-yield concepts associated with the Advanced Oncology Certified Nurse Practitioner (AOCNP) examination. Across 33 pages, the material covers oncology pharmacology and chemotherapy toxicities, monoclonal antibodies, EGFR and VEGF inhibitors, antimetabolites, alkylating agents, mitotic inhibitors, antiemetic therapy, gastrointestinal toxicities, myelosuppression, febrile neutropenia, extravasation, radiation effects, cancer genetics, screening, prevention, staging, clinical trials, ethics, and advanced oncology practice.
A major portion of the material focuses on recognizing and managing oncologic emergencies and treatment complications, including tumor lysis syndrome, DIC, SIADH, superior vena cava syndrome, cardiac tamponade, spinal cord compression, hypercalcemia, brain metastases, increased intracranial pressure, neutropenic complications, and electrolyte abnormalities. The document also reviews chemotherapy and targeted-therapy adverse effects involving agents such as oxaliplatin, bevacizumab, cetuximab, cytarabine, docetaxel, 5-FU, vincristine, doxorubicin, cisplatin, and obinutuzumab.
Additional questions address cancer risk assessment and prevention, including the Gail, Claus, Tyrer-Cuzick, and MMRpro models; BRCA1/2 and hereditary cancer concepts; HER2 testing; colorectal, cervical, breast, lung, and prostate cancer screening; and primary, secondary, and tertiary cancer prevention. Students also receive review material on clinical trial phases, CPT, HCPCS and ICD-10 concepts, ethical principles, learning domains, postoperative oncology care, palliative care, and selected cancer staging concepts.
The subject matter is relevant to the knowledge base expected in advanced oncology nursing. The Oncology Nursing Certification Corporation (ONCC) describes AOCNP as the Advanced Oncology Certified Nurse Practitioner certification and states that its certification examination uses a formal test content outline. The ONCC also publishes a dedicated 2026 AOCNP reference list, identifying resources used in developing examination items.
For authoritative supplementary study, ONCC's published AOCNP references include Baldwin, Coleman, and Garzo Saria's Advanced Oncology Nursing Certification Review and Resource Manual, 3rd edition (Oncology Nursing Society, 2023); Camp-Sorrell, Hawkins, and Cope's Clinical Manual for the Oncology Advanced Practice Nurse, 4th edition (Oncology Nursing Society, 2022); DeVita, Lawrence, and Rosenberg's Cancer: Principles and Practice of Oncology, 11th edition; Newton, Hickey, and Brant's Mosby's Oncology Nursing Advisor, 3rd edition; and Olsen et al.'s Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice, 2nd edition. The Oncology Nursing Society specifically describes its Advanced Oncology Nursing Certification Review and Resource Manual as a study and clinical resource offering comprehensive preparation for advanced oncology certification examinations, including AOCNP.
Relevant students: This document is most relevant to nurse practitioners preparing for AOCNP certification, graduate-level oncology nursing students, oncology APRNs, adult oncology nurse practitioners, family or adult-gerontology NPs moving into oncology practice, and advanced practice nursing students seeking focused review of cancer treatment, symptom management, oncologic emergencies, cancer prevention, genetics, and pharmacology. ONCC eligibility information confirms that AOCNP certification is designed for appropriately educated nurse practitioners practicing in adult oncology, so this material is particularly applicable to advanced rather than entry-level oncology nursing study.
Keywords:
AOCNP 2026, AOCNP 2027, AOCNP exam questions, AOCNP questions and answers, AOCNP study guide, AOCNP exam preparation, Advanced Oncology Certified Nurse Practitioner, oncology certification exam, oncology nurse practitioner, advanced oncology nursing, oncology practice questions, chemotherapy side effects, oncology pharmacology, oncologic emergencies, tumor lysis syndrome, febrile neutropenia, SIADH, spinal cord compression, cancer genetics, cancer screening, cancer prevention, monoclonal antibodies, EGFR inhibitors, VEGF inhibitors, cancer staging, clinical trials, myelosuppression, oncology nursing review, ONCC certification, advanced practice oncology
Content preview
AOCNP 2026/2027 Expert
Verifed Ace the Test
Side effects of oxaliplatin - ANSWER ✔✔Neuropathy
Cumulative risk for Infusion reaction
Cold sensitivity
Side effects of avastin - ANSWER ✔✔HTN
Nasal perforation
Delayed wound healing
Proteinuria
,Side effects of cetuximab - ANSWER ✔✔Acne form rash w/ risk of
infection
Hypersensitivity
Alopecia, hair changes, long eyelashes
Nail changes (paronychia) and fissures
Nanotechnology - ANSWER ✔✔the branch of engineering that deals
with things smaller than 100 nanometers (especially with the
manipulation of individual molecules)
EGFR class effects - ANSWER ✔✔Inflammatory rash
Diarrhea
Hypomagnesemia
Interstitial lung disease
Examples of antimetabolites - ANSWER ✔✔Fluorouracil,
Methotrexate, gemzar, cytarabine, capcitabine
Side effects of antimetabolites - ANSWER ✔✔Bone marrow
suppression
Mucositis- stomatitis, diarrhea
Examples of alkylating agents - ANSWER ✔✔Cyclophosphamide
,Cisplatin
Side effects of alkylation agents - ANSWER ✔✔Bone marrow
suppression
Damage to reproductive organs
examples of mitotic inhibitors - ANSWER ✔✔Taxol
Taxotere
Vincristine
Side effects of mitotic inhibitors - ANSWER ✔✔Neuropathy
Many are vesicants
examples of antitumor antibiotics - ANSWER ✔✔Doxorubicin
Bleomycin
Side effects of antitumor antibiotics - ANSWER ✔✔Bone marrow
suppression
Damage to cardiac myocytes
Most are vesicants
2 portions of monoclonal antibodies - ANSWER ✔✔The fab portion
The FC portion
COPYRIGHT©NINJANERD 2026/2027. YEAR PUBLISHED 2026. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE. PRIVACY
STATEMENT. ALL RIGHTS RESERVED
3
, Fab portion - ANSWER ✔✔antigen-binding portion of antibody.
Specific for each antigen.
Fc portion - ANSWER ✔✔Calls and binds immune effector cells to
the antigen to kill it
Principle ways immune cells kill antigen containing cells? - ANSWER
✔✔ADCC
CDC
Albumin measures - ANSWER ✔✔Protein stores
What does serum prealbumin measure? - ANSWER ✔✔Protein
depletion
What does serum transferrin measure? - ANSWER ✔✔Reflects the
body's ability to make serum protein
Recommended medications for low risk emetogenic chemo -
ANSWER ✔✔-it is recommended to use a single agent such as
steroid, Regina, compazine, or 5-HT3 antagonist
Recommended medications for moderate risk emetogenic chemo -
ANSWER ✔✔- combo 5-HT3 antagonist, steroid, +\- NK1 antagonist,
+\- anxiolytic